Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, James C Yang, Federico Longo, Maria de Miguel, Mariano Ponz-Sarvise, Myung-Ju Ahn, Mahmut Gumus, Stephane Champiat, Antoine Italiano, Sebastien Salas, Ruth Perets, Cagatay Arslan, Byoung C Cho, Stefan Evers, Christophe Boetsch, Daniel Marbach, David Dejardin, Nassim Sleiman, Caroline Ardeshir, Muriel Richard, Jehad Charo, Anton Kraxner, Nino Keshelava, Volker Teichgräber, Victor Moreno
PURPOSE: Reported here are results from the esophageal squamous cell carcinoma (SCC) cohort of a Phase II, non-comparative, basket study, evaluating the anti-tumor activity and safety of FAP-IL2v plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721). EXPERIMENTAL DESIGN: Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-1; measurable metastatic, persistent, or recurrent esophageal SCC; progression on ≥1 prior therapy; and were checkpoint inhibitor naive...
May 6, 2024: Clinical Cancer Research